AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio has raised $70.8M in total funding. The most recent round was Series B. The last funding was announced in September 2026.
AnaCardio's investors include LLD Nybohov Invest AB, Novo Holdings, Innovestor, Pureos Bioventures, Sound Bioventures.
AnaCardio is headquartered in Solna, Sweden.
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
AnaCardio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AnaCardio — Funding & Investors." VCBacked, September 30, 2026, https://www.vcbacked.co/company/anacardio. Accessed October 14, 2026.
VCBacked. (2026). AnaCardio — Funding & Investors. Retrieved October 14, 2026, from https://www.vcbacked.co/company/anacardio
{{cite web |title=AnaCardio — Funding & Investors |url=https://www.vcbacked.co/company/anacardio |website=VCBacked |access-date=October 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated